Market Access Impact: HIV (US) 2018
Market barriers affect just over 1 in 10 HIV prescriptions. Is your brand losing out?
In the US, where market barriers affect just over one in 10 HIV prescriptions, the top brand has a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: HIV (US) [2018].
Based on a survey of 100 infectious disease specialists, the report covers 12 major therapies from Gilead, ViiV, Merck & Co., BMS and Janssen Biotech. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Top Takeaways
Market Access Impact: HIV (US) explores key issues affecting HIV drug manufacturers. You’ll learn:
How barriers affect market access:
We surveyed 100 US-based infectious disease specialists, chosen from the largest community of validated physicians in the world. All respondents have:
All respondents:
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
In the US, where market barriers affect just over one in 10 HIV prescriptions, the top brand has a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: HIV (US) [2018].
Based on a survey of 100 infectious disease specialists, the report covers 12 major therapies from Gilead, ViiV, Merck & Co., BMS and Janssen Biotech. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.
Top Takeaways
- Barriers affect just over one in 10 prescriptions: But is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
- Only one brand sees a significant share increase: Four brands gain share thanks to barriers, but the top-gaining brand sees a much bigger bump than the other three.
- One brand sees a significant loss: This brand loses 2.5% of its market share because of barriers. Why? And can this be prevented?
- Eliminating barriers would have limited impact at the top and bottom of the table: The leading brand relies on other brands losing out, but removing barriers wouldn’t have a massive impact on market share for other brands. What does this mean to the overall makeup of the market?
- Two brands have a perception problem: Between a quarter and a third of surveyed doctors would not prescribe these brands, leaving other brands to capture market share.
- Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate; Gilead)
- Descovy (emtricitabine/tenofovir alafenamide; Gilead)
- Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
- Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide; Gilead)
- Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
- Tivicay (dolutegravir; ViiV Healthcare)
- Isentress (raltegravir; Merck & Co.)
- Prezcobix (darunavir/cobicistat; Janssen Biotech)
- Edurant (rilpivirine; Janssen Biotech)
- Prezista (darunavir; Janssen Biotech)
- Reyataz (atazanavir; Bristol-Myers Squibb)
- Juluca (dolutegravir/rilpivirine,ViiV Healthcare)
Market Access Impact: HIV (US) explores key issues affecting HIV drug manufacturers. You’ll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
We surveyed 100 US-based infectious disease specialists, chosen from the largest community of validated physicians in the world. All respondents have:
All respondents:
- Have been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients in total in the last month
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. WHAT ARE MARKET BARRIERS?
2. ABOUT THIS REPORT
3. ABOUT THE SURVEY
4. BRANDS INCLUDED IN THE SURVEY
5. EXECUTIVE SUMMARY
2. ABOUT THIS REPORT
3. ABOUT THE SURVEY
4. BRANDS INCLUDED IN THE SURVEY
5. EXECUTIVE SUMMARY
